-transparent.png){kind=logo}
A patient with rheumatoid arthritis presented with pancytopenia 3 weeks after initiation of low-dose methotrexate administered orally. She had minimal renal insufficiency and hypoalbuminemia prior to initiation of methotrexate therapy, and had received a nonsteroidal anti-inflammatory drug concurrently. Bone marrow recovery occurred within 3 weeks. Patients receiving low-dose methotrexate therapy for rheumatoid arthritis require early monitoring for bone marrow injury, especially those who have risk factors for possible methotrexate toxicity.
Related Publications
G C Doolittle, and
K M Simpson, and
H B Lindsley
August 1992,
The Journal of rheumatology,
G C Doolittle, and
K M Simpson, and
H B Lindsley
May 1996,
Revue du rhumatisme (English ed.),
G C Doolittle, and
K M Simpson, and
H B Lindsley
September 1996,
Presse medicale (Paris, France : 1983),
G C Doolittle, and
K M Simpson, and
H B Lindsley
January 2002,
The Annals of pharmacotherapy,
G C Doolittle, and
K M Simpson, and
H B Lindsley
February 1996,
Arthritis and rheumatism,
G C Doolittle, and
K M Simpson, and
H B Lindsley
December 2001,
The Annals of pharmacotherapy,
G C Doolittle, and
K M Simpson, and
H B Lindsley
November 1985,
Seminars in arthritis and rheumatism,
G C Doolittle, and
K M Simpson, and
H B Lindsley
August 1988,
Australian and New Zealand journal of medicine,
G C Doolittle, and
K M Simpson, and
H B Lindsley
July 1995,
The Journal of rheumatology,
G C Doolittle, and
K M Simpson, and
H B Lindsley
September 1990,
Revista clinica espanola,
